GB201021979D0 - New compound - Google Patents

New compound

Info

Publication number
GB201021979D0
GB201021979D0 GB201021979A GB201021979A GB201021979D0 GB 201021979 D0 GB201021979 D0 GB 201021979D0 GB 201021979 A GB201021979 A GB 201021979A GB 201021979 A GB201021979 A GB 201021979A GB 201021979 D0 GB201021979 D0 GB 201021979D0
Authority
GB
United Kingdom
Prior art keywords
inhibitor
antagonist
agonist
receptor
ccr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB201021979A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pulmagen Therapeutics Synergy Ltd
AstraZeneca AB
Original Assignee
Pulmagen Therapeutics Synergy Ltd
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pulmagen Therapeutics Synergy Ltd, AstraZeneca AB filed Critical Pulmagen Therapeutics Synergy Ltd
Priority to GB201021979A priority Critical patent/GB201021979D0/en
Publication of GB201021979D0 publication Critical patent/GB201021979D0/en
Priority to PCT/GB2011/052560 priority patent/WO2012085583A1/en
Ceased legal-status Critical Current

Links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides a pharmaceutical product, kit or composition comprising a first active ingredient which is N-Butyl-N-(2-(2-(5-hydroxy-3-oxo-3,4-dihydro-2H- benzo[b][1,4]oxazin-8-yl)ethylamino)ethyl)-3-(3-(2-(4-(2-isopropylthiazole-4-carbonyl)-1-5 oxa-4,9-diazaspiro[5.5]undecan-9-yl)ethyl)phenethoxy)propanamide or a salt thereof, and a second active ingredient selected from: a non-steroidal Glucocorticoid Receptor (GR Receptor) Agonist; an antioxidant; a CCR1 antagonist; a chemokine antagonist (not CCR1); a corticosteroid; a CRTh2 antagonist; a DP1 antagonist; an Histone Deacetylase activator; an IKK2 kinase inhibitor; a COX inhibitor; a lipoxygenase inhibitor; a leukotriene receptor antagonist; an MPO inhibitor; a PDE4 inhibitor; a PPAR? agonist; a protease inhibitor; a p38 inhibitor, a selective glucocorticoid receptor agonist (SEGRA), a Statin; a thromboxane antagonist; a vasodilator; or, an ENAC blocker (Epithelial Sodium-channel blocker); and its use in the treatment of respiratory disease.
GB201021979A 2010-12-23 2010-12-23 New compound Ceased GB201021979D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB201021979A GB201021979D0 (en) 2010-12-23 2010-12-23 New compound
PCT/GB2011/052560 WO2012085583A1 (en) 2010-12-23 2011-12-22 New compound

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201021979A GB201021979D0 (en) 2010-12-23 2010-12-23 New compound

Publications (1)

Publication Number Publication Date
GB201021979D0 true GB201021979D0 (en) 2011-02-02

Family

ID=43599002

Family Applications (1)

Application Number Title Priority Date Filing Date
GB201021979A Ceased GB201021979D0 (en) 2010-12-23 2010-12-23 New compound

Country Status (2)

Country Link
GB (1) GB201021979D0 (en)
WO (1) WO2012085583A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20110083U1 (en) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire PLATE FOR THE CONSTRUCTION OF TRUCKS FOR AIRPLANES
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
BR112015013628A2 (en) 2012-12-18 2017-07-11 Almirall Sa cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
TWI643853B (en) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 SALTS OF 2-AMINO-1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2(1H)-ONE DERIVATIVES HAVING BOTH β2 ADRENERGIC RECEPTOR AGONIST AND M3 MUSCARINIC RECEPTOR ANTAGONIST ACTIVITIES
TWI641373B (en) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 SALTS OF 2-AMINO-1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2(1H)-ONE DERIVATIVES HAVING BOTH MUSCARINIC RECEPTOR ANTAGONIST AND β2 ADRENERGIC RECEPTOR AGONIST ACTIVITIES
TW201517906A (en) 2013-07-25 2015-05-16 Almirall Sa Combinations comprising MABA compounds and corticosteroids
TW201617343A (en) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 New bicyclic derivatives having [beta]2 adrenergic agonist and M3 muscarinic antagonist activities
CN109195975B (en) * 2016-09-30 2022-01-04 四川海思科制药有限公司 Diazaspiro [5.5] undecane derivative and application thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB432097A (en) 1935-03-28 1935-07-19 John Rea Chance Improvements in brackets for the handles of perambulators
CN1390255A (en) 1999-11-24 2003-01-08 武田药品工业株式会社 Use of disease-associated gene
DE60030768T2 (en) 1999-12-24 2007-11-08 F. Hoffmann-La Roche Ag NITRIL DERIVATIVES AS CATHEPSIN K HEMMER
GB0003154D0 (en) 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
CO5300399A1 (en) 2000-02-25 2003-07-31 Astrazeneca Ab HETEROCICLIOCS CONTAINING NITROGEN, PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR028948A1 (en) 2000-06-20 2003-05-28 Astrazeneca Ab NEW COMPOUNDS
AU2001281255B2 (en) 2000-08-14 2006-07-20 Ortho-Mcneil Pharmaceutical, Inc. Substituted pyrazoles
SE0100902D0 (en) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0102617D0 (en) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
SE0102616D0 (en) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
SE0104251D0 (en) 2001-12-14 2001-12-14 Astrazeneca Ab Novel compounds
SE0104331D0 (en) 2001-12-19 2001-12-19 Astrazeneca Ab Novel compounds
AR038703A1 (en) 2002-02-28 2005-01-26 Novartis Ag DERIVATIVES OF 5-PHENYLTIAZOL AND USE AS AN INHIBITOR OF QUINASA P I 3
AR039385A1 (en) 2002-04-19 2005-02-16 Astrazeneca Ab THIOXANTINE DERIVATIVES AS INHIBITORS OF MIELOPEROXIDASA
SE0300091D0 (en) 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
SE0300092D0 (en) 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
SE0301010D0 (en) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SE0301569D0 (en) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
CN1835942A (en) 2003-06-19 2006-09-20 金纳莱公司 Mucin synthesis inhibitors
EP1644326B1 (en) 2003-06-30 2016-11-02 Merck Canada Inc. Cathepsin cysteine protease inhibitors
SE0301963D0 (en) 2003-07-02 2003-07-02 Astrazeneca Ab New compounds
SA04250253B1 (en) 2003-08-21 2009-11-10 استرازينيكا ايه بي Substiuted phenoxacetic as pharmaceutced compunds for treating respiratory diseases such as asthma and copd
SE0302486D0 (en) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
GB0324790D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Amide derivatives
DE602004031037D1 (en) 2003-11-19 2011-02-24 Array Biopharma Inc HETEROCYCLIC INHIBITORS OF MEK
MXPA06012829A (en) 2004-05-04 2007-01-26 Warner Lambert Co Pyrrolyl substituted pyrido[2,3-d]pyrimidin-7-ones and derivatives thereof as therapeutic agents.
SE0401762D0 (en) 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
PL1831149T3 (en) 2004-12-23 2012-06-29 Galderma Res & Dev Novel ligands that modulate rar receptors and use thereof in human medicine and in cosmetics
WO2006091112A1 (en) 2005-02-22 2006-08-31 Genesis Reasearch And Development Corporation Limited Compositions for the delivery of rna interference molecules and methods for their use
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
CA2635830A1 (en) 2006-01-23 2007-07-26 Laboratoires Serono S.A. Thiazole derivatives and use thereof
UY30267A1 (en) 2006-04-13 2007-11-30 Astrazeneca Ab NEW DERIVATIVES OF THIOXANTINE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION PROCEDURES AND APPLICATIONS
WO2007123939A2 (en) 2006-04-19 2007-11-01 Laboratoires Serono S.A. Novel arylamino n-heteraryls as mek inhibitors
TW200808771A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
EP2032597A2 (en) 2006-06-16 2009-03-11 UMC Utrecht Holding B.V. Fplr-1 inhibitors for use in diseases involving amyloid-induced inflammatory events (flipr and flipr-like) and immunecomplex-mediated diseases
WO2008010765A1 (en) 2006-07-19 2008-01-24 Astrazeneca Ab Novel tricyclic spiropiperidine compounds, their synthesis and their uses as modulators of chemokine receptor activity
JP2010502739A (en) 2006-09-07 2010-01-28 パリオン・サイエンシィズ・インコーポレーテッド Improvement of mucosal hydration and mucus clearance by treatment with sodium channel inhibitors and osmotic regulators
WO2008064136A2 (en) 2006-11-17 2008-05-29 Acadia Pharmaceuticals Inc. Compounds with activity at retinoic acid receptors
SE0602739L (en) 2006-12-18 2008-03-25 Nilar Int Ab A system for reducing power in a battery stack arrangement, and a vehicle equipped with such a system
JO2754B1 (en) 2006-12-21 2014-03-15 استرازينكا ايه بي Indazolyl amide derivatives for the treatment of glucocorticoid receptor mediated disorders
SA08280783B1 (en) 2007-01-11 2011-04-24 استرازينيكا ايه بي Pyridopyrimidine Derivatives as PDE4 Inhibitors
CN101842361B (en) 2007-06-27 2013-06-05 阿斯利康(瑞典)有限公司 Pyrazinone derivatives and their use in the treatment of lung diseases
NZ584160A (en) 2007-10-04 2011-05-27 Astrazeneca Ab Steroidal [3,2-c] pyrazole compounds, with glucocorticoid activity
TWI445705B (en) 2008-05-20 2014-07-21 Astrazeneca Ab Phenyl and benzodioxinyl substituted indazoles derivatives
GB0913342D0 (en) * 2009-07-31 2009-09-16 Astrazeneca Ab Compounds - 801

Also Published As

Publication number Publication date
WO2012085583A1 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
GB201021992D0 (en) Compound
GB201021979D0 (en) New compound
WO2009037503A3 (en) New combination - 012 for the treatment of respiratory diseases
AR065277A1 (en) COMBINATIONS OF BENZOTIAZOLONA AGONISTA 2-BETA-ADRENOCEPTOR
EA201000702A1 (en) SOME DERIVATIVES 2-PYRAZINONE AND THEIR APPLICATION AS NEUTROFIL ELASTASIS INHIBITORS
CL2004000655A1 (en) COMPOUNDS DERIVED FROM PIPERIDIN-2-ONA 1,6-DISUSTITUTED, ITS SALTS, PHARMACEUTICAL COMPOSITION, AGONISTS OF THE EP4 RECEIVER; USE OF COMPOUNDS TO TREAT OCULAR HYPERTENSION, GLAUCOMA.
NO20064156L (en) Indazole carboxamide compounds as 5-HT 4 receptor agonists
NO20063620L (en) Arylaniline derivatives as beta2 adrenergic receptor agonists
EA201290255A1 (en) METHODS AND COMPOSITIONS FOR CANCER TREATMENT
EA200702541A1 (en) ETHYL ESTER POLYMORPHORMS 3 - [(2 - {[4- (HEXILOXYCARBONYLAMINOIMINOMETHYL) PHENYLAMINO] METHYL} -1-METHYL-1H-BENZIMIDAZOL-5-CARBONYL) PYRIDIN-2-I-BENYMIDAZOL-5-CARBONYL) Pyridine-2-I-IHYDIHYRODYOL-5-CARBONYL-Pyridine-2-I-BPHYHIRODYOL-5-CARBONYL-Pyridine-2-I-pyrimidazole-5-Carbonyl) Pyridine-2-I-Pyrihydromethyl-1-Benzimidazole-5-Carbonyl) Pyridine-2-I-Pyrihydromethylamino-5-Carbonyl) Pyridine-2-I-Benzimidazole-5-Carbonyl) Pyridine-2-I-Pyrimidazole-5-Carbonyl) Pyridine-2-I;
CL2007002867A1 (en) COMPOUNDS DERIVED FROM 2- (BENCIMIDAZOLIL) PURINA, INHIBITORS OF JANUS QUINASA 3; PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM; AND ITS USE TO TREAT AUTOIMMUNE, INFLAMMATORY, CARDIOVASCULAR DISEASES, IMPLANT REJECTION, AMONG OTHERS.
NO20073259L (en) New 4-arylaminopyndondenate as MEK inhibitors of hyperproliferative disorders
MA44759B1 (en) POLYMORPH FORM OF N-(6-(2-HYDROXYPROPAN-2-YL)-2-[2-(METHYLSULFONYL)ETHYL]-2H-INDAZOL-5-YL)-6-(TRIFLUOROMETHYL)PYRIDINE-2-CARBOXAMIDE
JO3021B1 (en) 4-[4-({[ 4- chloro-3- (trifluoromethyl) phenyl] carbamoyl}lamino)-3- fluoromethyl]-N-methylpyridine -2- carboxamide monohydrate
CL2004000234A1 (en) DERIVATIVE COMPOUNDS 3- (PIRIDIN-2-IL) -4-HETEROARIL-PIRAZOL SUBSTITUTED, ANTAGONISTS OF AIK5 AND / OR AIK4; PHARMACEUTICAL COMPOSITION AND USE OF THE COMPOUND IN THE TREATMENT OF FIBROTIC DISORDERS AS SCLERODERMIA, LUPUS NEFRITICO, CICATRIZACION DE HERID
CY1113734T1 (en) CHEMICAL COMPOUNDS
WO2006034093A3 (en) 3- (2-acylamino-1-hydroxyethyl)- morpholine derivatives and their use as bace inhibitors
BRPI0615163A2 (en) compound, pharmaceutical composition, use of the compound, and methods for treating mglur5-mediated disorders and for inhibiting activation of mglur5 receptors
WO2007022380A3 (en) Bis-aryl amide compounds and methods of use
BR0313923A (en) 3- (Sulfonamidoethyl) indole derivatives for use as glucocorticoid mimetics in the treatment of inflammatory, allergic and proliferative diseases
CL2010001608A1 (en) Compounds derived from 2- (3- (5-oxo-4,5-dihydro-pyrazin-2-yl) -phenyl) -4,5-dihydro-2h-isoquinolin-1-one and 2- (3- (5 -oxo-4,5-dihydro-pyrazin-2-yl) -phenyl) -3,4-dihydro-2h-isoquinolin-1-one, kinase inhibitors; pharmaceutical composition; Useful in the treatment of inflammatory and / or immune pathological conditions.
DK1485378T3 (en) Piperazinyl, piperidinyl and morpholinyl derivatives as novel inhibitors of histone deacetylase
ATE526318T1 (en) FARNESOID-X RECEPTOR AGONISTS
CL2007003265A1 (en) COMPOUNDS DERIVED FROM 1H-PIRAN [2,3-D] PIRIMIDIN-2,4,7-TRIONA; AND PHARMACEUTICAL COMPOSITION, USEFUL FOR THE TREATMENT OF METABOLIC SYNDROME, DYSLIPIDEMIA AND CARDIOVASCULAR DISEASES BETWEEN OTHERS.
WO2007073303A3 (en) Novel benzimidazole derivatives as vanilloid receptor 1 (vrl) inhibitors

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)